Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE)

被引:1
作者
Qian, Kun [1 ]
Chen, Qi-Rui [2 ,3 ]
He, Ming [4 ]
Wang, Zi-Tong [5 ]
Liu, Yu [6 ]
Liang, Hua-Gang [7 ]
Su, Zhi-Yong [8 ]
Cui, Yu-Shang [9 ]
Liu, Li-Jun [10 ]
Zhang, Yi [1 ]
机构
[1] Capital Med Univ, Xuanwu Hosp, Dept Thorac Surg, 45 Changchun St, Beijing 100053, Peoples R China
[2] Capital Med Univ, Dept Thorac Surg, Beijing Inst Resp Med, Beijing, Peoples R China
[3] Capital Med Univ, Beijing Chao Yang Hosp, Beijing, Peoples R China
[4] Hebei Med Univ, Dept Thorac Surg, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[5] Capital Med Univ, Beijing Chest Hosp, Dept Thorac Surg, Beijing, Peoples R China
[6] Handan Cent Hosp, Dept Thorac Surg 2, Handan, Hebei, Peoples R China
[7] First Hosp Qinhuangdao, Dept Thorac Surg, Qinhuangdao, Hebei, Peoples R China
[8] Chifeng Univ, Dept Thorac Surg, Affiliated Hosp, Chifeng, Neimenggu, Peoples R China
[9] Peking Union Med Coll Hosp, Dept Thorac Surg, Beijing, Peoples R China
[10] Hebei Prov Peoples Hosp, Dept Thorac Surg, Shijiazhuang, Hebei, Peoples R China
关键词
Adenocarcinoma; Adjuvant therapy; Epidermal growth factor receptor mutation; Icotinib; Non-small-cell lung cancer; GROWTH-FACTOR RECEPTOR; DELETION POLYMORPHISM; TARGETED THERAPIES; CANCER PATIENTS; EXON; 19; GEFITINIB; RESISTANCE; SAFETY; BIM; OSIMERTINIB;
D O I
10.1007/s10637-022-01316-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The survival benefit of icotinib (an oral epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) in patients with advanced lung cancer has been confirmed in several studies. This study (ICAPE) evaluated the efficacy of icotinib as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma. Patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma were enrolled in the multicenter, open-label, single-arm, phase II study. Eligible patients received oral icotinib 125 mg thrice daily for 1.5 years after complete surgical resection. The primary endpoint was disease-free survival (DFS). Between March 2014 and January 2018, 79 patients were enrolled. The median follow-up time was 39.7 months with a median DFS and overall survival (OS) of 41.4 months (95% CI: 33.6-51.8) and 67.0 months (95% CI: 21.2-not reached [NR]), respectively. The 1-year, 3-year, and 5-year OS rates were 100%, 83.3%, and 61.7%, respectively. No significant difference was found in the median DFS between patients with Bcl-2 interacting mediator of cell death (BIM) mutant-type and wild-type (NR vs. 41.7 months; p = 0.75). No significant difference was found in the median DFS according to EGFR mutation types. Icotinib as adjuvant therapy demonstrated a favorable survival benefit in patients with stage IIA-IIIA EGFR-mutant non-small-cell lung adenocarcinoma, indicating that icotinib might be a promising treatment option for this patient population. The optimal adjuvant duration of icotinib is still not clear and needs more incoming data to answer.
引用
收藏
页码:44 / 52
页数:9
相关论文
共 36 条
  • [1] Bim-targeted cancer therapy: A link between drug action and underlying molecular changes
    Akiyama, Toru
    Dass, Crispin R.
    Choong, Peter F. M.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12) : 3173 - 3180
  • [2] EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non-Small Cell Lung Cancer Patients
    Choi, Yong Won
    Jeon, So Yeon
    Jeong, Geum Sook
    Lee, Hyun Woo
    Jeong, Seong Hyun
    Kang, Seok Yun
    Park, Joon Seong
    Choi, Jin-Hyuk
    Koh, Young Wha
    Han, Jae Ho
    Sheen, Seung Soo
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (04): : 385 - 390
  • [3] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [4] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Gelatti, Ana C. Z.
    Drilon, Alexander
    Santini, Fernando C.
    [J]. LUNG CANCER, 2019, 137 : 113 - 122
  • [5] Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
    Harrison, Peter T.
    Vyse, Simon
    Huang, Paul H.
    [J]. SEMINARS IN CANCER BIOLOGY, 2020, 61 : 167 - 179
  • [6] Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
    He, Jianxing
    Su, Chunxia
    Liang, Wenhua
    Xu, Shidong
    Wu, Lin
    Fu, Xiangning
    Zhang, Xiaodong
    Ge, Di
    Chen, Qun
    Mao, Weimin
    Xu, Lin
    Chen, Chun
    Hu, Bing
    Shao, Guoguang
    Hu, Jian
    Zhao, Jian
    Liu, Xiaoqing
    Liu, Zhidong
    Wang, Zheng
    Xiao, Zemin
    Gong, Taiqian
    Lin, Wen
    Li, Xingya
    Ye, Feng
    Liu, Yang
    Ma, Haitao
    Huang, Yunchao
    Zhou, Jianying
    Wang, Zhonglin
    Fu, Junke
    Ding, Lieming
    Mao, Li
    Zhou, Caicun
    [J]. LANCET RESPIRATORY MEDICINE, 2021, 9 (09) : 1021 - 1029
  • [7] Lung cancer: current therapies and new targeted treatments
    Hirsch, Fred R.
    Scagliotti, Giorgio V.
    Mulshine, James L.
    Kwon, Regina
    Curran, Walter J.
    Wu, Yi-Long
    Paz-Ares, Luis
    [J]. LANCET, 2017, 389 (10066) : 299 - 311
  • [8] A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
    Hu, Xingsheng
    Han, Baohui
    Gu, Aiqin
    Zhang, Yiping
    Jiao, Shun Chang
    Wang, Chang-li
    He, Jintao
    Jia, Xueke
    Zhang, Li
    Peng, Jiewen
    Wu, Meina
    Ying, Kejing
    Wang, Junye
    Ma, Kewei
    Zhang, Shucai
    You, Changxuan
    Tan, Fenlai
    Wang, Yinxiang
    Ding, Lieming
    Sun, Yan
    [J]. LUNG CANCER, 2014, 86 (02) : 207 - 212
  • [9] Comparison of the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer according to the Type of Epidermal Growth Factor Receptor Mutation
    Igawa, Satoshi
    Kasajima, Masashi
    Ishihara, Mikiko
    Kimura, Michiko
    Hiyoshi, Yasuhiro
    Asakuma, Maiko
    Otani, Sakiko
    Katono, Ken
    Sasaki, Jiichiro
    Masuda, Noriyuki
    [J]. ONCOLOGY, 2014, 87 (04) : 215 - 223
  • [10] Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib
    Jackman, David M.
    Yeap, Beow Y.
    Sequist, Lecia V.
    Lindeman, Neal
    Holmes, Alison J.
    Joshi, Victoria A.
    Bell, Daphne W.
    Huberman, Mark S.
    Halmos, Balazs
    Rabin, Michael S.
    Haber, Daniel A.
    Lynch, Thomas J.
    Meyerson, Matthew
    Johnson, Bruce E.
    Jaenne, Pasi A.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (13) : 3908 - 3914